Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK008 haploidentical HCT with HSV-Tk donor lymphocyte add-back versus other T-cell repletion strategies
2006-006862-41Phase 3Terminated
- Sponsor
- MolMed
- Start
- Dec 2007
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nalotimagene carzadenotucel in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by MolMed. Primary endpoints: Cumulative incidence of extensive chronic graft-versus-host disease and Overall survival. Started Dec 2007; status: terminated.
02
Drugs
nalotimagene carzadenotucel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2006-006862-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006862-41.